Navigation Links
New Engineered Drug Shows Promise in Treating Lymphocytic Leukaemia

A recent research has found that a new type of engineered drug may have the potential to treat chronic lymphocytic leukaemia.

The study by researchers at the Ohio State University Comprehensive Cancer Center was published online in the journal Blood.

The research has established that an engineered drug candidate is promising in treating lymphocytic leukemia in both test tube and early animal tests.

The agent represents a new class of agents called small modular immunopharmaceuticals. This agent, which is called CD37-SMIP, targets a protein called CD37 on the surface of these leukemia cells.

The study shows that the agent can successfully attach to the protein on the leukemia cells and destroy them. It works both by activating the cells' self-destruction and by causing a particular class of immune cells to attack them.

In an animal model, the agent worked uniformly over and above the drug rituximab, now routinely used to treat chronic lymphocytic leukemia (CLL) patients. Rituximab targets a different protein on leukemia cells.

"Our findings have significant implications for the treatment of CLL and related malignancies," says principal investigator John C. Byrd, director of the hematologic malignancies program at Ohio State 's James Cancer Hospital and Solove Research Institute.

Overall, Byrd says, "the findings point out that this could be an effective agent for treating CLL and other malignancies, such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia when they have expression of the CD37 protein."

The laboratory portion of the study used CLL cells from patients, laboratory-grown non-Hodgkin's lymphoma cells and acute lymphocytic leukemia cells.

This research showed that the agent kills leukemia cells directly by triggering their self-destruction through the process of apoptosis.

The study also found that thi s self-destruction happens differently from how other drugs cause apoptosis. Most drugs cause cells to self-destruct by triggering a cell mechanism that requires enzymes called caspases. This new agent, however, works through a mechanism that does not call for caspases.

"This is exciting because it means that this agent may benefit patients who are resistant to other CLL drugs," says co-author Natarajan Muthusamy, a research scientist with Ohio State's Comprehensive Cancer Center. "It also suggests that it might work well in combination with other drugs, as well as alone."

The findings also show that after the agent joins with the cancer cells, it attracts immune cells called natural killer cells, which also devastate the leukemia cells.


'"/>




Related medicine news :

1. Regulators Object Drug Produced from Genetically Engineered Farm Animals
2. Engineered Tissue Implants benefited Knee Injured patients
3. Indian American have Genetically Engineered Edible Cottonseed
4. USDA Gives Go-Ahead to Market Controversial Genetically Engineered Rice, LL601
5. Xylitol To Be Produced By Genetically Engineered E. Coli
6. Genetic-Engineered Cows Resist Mad Cow Disease
7. Researchers Explore the Effect of Engineered Immune Cells on HIV
8. Tissue Engineered Scaffolding Allows Reproduction of Cartilage Tissue
9. Experimental treatment for Ebola Virus Shows promising results in mice
10. New Prostate Cancer Vaccine Shows Promise
11. Ebola Treatment Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... ... ... The Dream Builders Project, a 501(c)3 nonprofit organization based in Los Angeles, ... Mexico on Saturday, May 21st. The volunteers took the children out for the day ... 15 volunteers traveled from Los Angeles to Tijuana, Mexico for the day in the ...
(Date:5/24/2016)... ... 2016 , ... Global Lyme Alliance (GLA), a leading nonprofit ... has named Scott Santarella as its new CEO. , Santarella is former ... San Francisco, where he successfully helped to grow the organization from a regional ...
(Date:5/24/2016)... ... ... PhysicianOne Urgent Care, advocators in helping their patients lead the healthiest lives possible, updates ... spring. , The official tick season kicks off in May across the states ... themselves to their prey while they feed off their blood. Like other similar biting ...
(Date:5/24/2016)... ... May 24, 2016 , ... Applications ... multiplex immunoassays are widely used for cell and protein analysis. Keeping updated on ... quality and efficiency in these areas. , LabRoots introduces a new complementary ...
(Date:5/23/2016)... ... May 23, 2016 , ... On the occasion of his 25th Anniversary of ... weight loss process: , New patients have a consultation and evaluation (done by Dr. ... evaluated. , Body Composition Analysis, There are 15 things that each patient gets checked ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... -- Global Paclitaxel Market 2016 Industry Research ... and the Paclitaxel analysis in this study is supported ... its players. This is the latest Paclitaxel ... current state of the industry while providing a basic ... industry chain structure. The Paclitaxel market analysis is provided ...
(Date:5/23/2016)... , May 23, 2016 The World Health ... PrePex device to include adolescents aged 13 years, and ... can be offered for adult and adolescent males in the ... . PrePex was the first male circumcision device to ... MedTech,s CEO, Eddy Horowitz said: " The ...
(Date:5/23/2016)... May 23, 2016   Purdue Pharma L.P. ... an agreement with Egalet Corporation and Acura Pharmaceuticals, ... part of the agreement the companies will exchange ... all three companies to develop and sell several ... "This agreement reflects the commitment of Purdue Pharma ...
Breaking Medicine Technology: